Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Patritumab Deruxtecan Does Not Improve Overall Survival in EGFR-Mutated NSCLC
June 1st 2025, 7:55pm
Patritumab deruxtecan did not improve OS vs platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic NSCLC.
First-Line Nivolumab Plus Ipilimumab Does Not Boost OS in Cisplatin-Ineligible Unresectable Urothelial Carcinoma
June 1st 2025, 7:47pm
Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.
Savolitinib Plus Osimertinib Hits PFS End Point in EGFR-Mutated, MET-Amplified NSCLC After Disease Progression With an EGFR TKI
June 1st 2025, 7:35pm
Savolitinib plus osimertinib was safe and effective in patients with EGFR-mutated, MET-amplified advanced NSCLC after disease progression on an EGFR TKI.
Glofitamab/GemOx Enhances OS and PFS vs Rituximab in R/R DLBCL
June 1st 2025, 7:31pm
Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.
Cilta-Cel Boosts Survival Vs SOC Across Key Subgroups of R/R Multiple Myeloma
June 1st 2025, 7:16pm
CARTITUDE-4 subgroup data further support cilta-cel’s positive benefit-risk profile in relapsed/refractory multiple myeloma.
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC
June 1st 2025, 6:33pm
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Nivolumab Plus Relatlimab Penetrates Blood-Brain Barrier in PD-(L)1-Refractory Melanoma With Brain Metastases
June 1st 2025, 5:00pm
Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.
Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC
June 1st 2025, 4:53pm
Sarah Cannon Research Institute
David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.
Indirect Comparisons Shows Relatlimab/Nivolumab Has Comparable Outcomes to Ipilimumab/Nivolumab in Advanced Melanoma
June 1st 2025, 4:37pm
The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.
Sintilimab/Chidamide Plus P-GemOx Shows Antitumor Activity in Treatment-Naive, Early-Stage Natural Killer/T-Cell Lymphoma
June 1st 2025, 4:16pm
Sintilimab/chidamide followed by P-GemOx demonstrated preliminary efficacy in treatment-naive, early-stage extranodal natural killer/T-cell lymphoma.
Adagrasib Plus Pembrolizumab Generates Responses in KRAS G12C+ NSCLC
June 1st 2025, 3:41pm
Adagrasib plus pembrolizumab was efficacious in patients with KRAS G12C-mutant NSCLC.
Preoperative PAXG Extends EFS in Resectable and Borderline Resectable Pancreatic Cancer
June 1st 2025, 2:00pm
Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.
Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer
June 1st 2025, 1:50pm
Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.
Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC
June 1st 2025, 12:19pm
TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.
Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer
June 1st 2025, 12:00pm
Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.
Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer
June 1st 2025, 12:00pm
Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.
Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma
June 1st 2025, 12:00pm
The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.
Postoperative Nivolumab Plus SOC Extends DFS in Resected, High-Risk Head and Neck Cancer
June 1st 2025, 12:00pm
Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
June 1st 2025, 1:26am
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC
June 1st 2025, 1:05am
A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.